Last reviewed 2026-04-20 · How we verify

TERAZOSIN HYDROCHLORIDE

Terazosin Hydrochloride is a marketed drug primarily indicated for symptomatic Benign Prostatic Hyperplasia (BPH). Its key strength lies in its established market presence and the key composition patent, which is set to expire in 2028. The primary risk is the potential increase in competition following the patent expiry.

At a glance

Approved indications

• Symptomatic Benign Prostatic Hyperplasia (BPH)
• Hypertension

Common side effects

• Asthenia
• Dizziness
• Somnolence
• Nasal congestion/Rhinitis
• Postural hypotension
• Impotence
• Blurred vision
• Nausea
• Peripheral edema
• Palpitations
• Chest pain
• Abdominal pain

Serious adverse events

• Arrhythmia
• Vasodilation
• Fever
• Facial edema
• Gout
• Arthritis
• Myalgia
• Bronchitis
• Epistaxis

Key clinical trials

• Terazosin And Metabolic Energetics in Parkinson's Disease (PHASE2)
• Terazosin for Dementia With Lewy Bodies (PHASE1, PHASE2)
• Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (EARLY_PHASE1)
• Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (PHASE2)
• Terazosin and Parkinson's Disease Extension Study (PHASE2)
• Terazosin And Metabolic Engagement in Parkinson's Disease (PHASE1, PHASE2)
• Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial (PHASE3)
• Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TERAZOSIN HYDROCHLORIDE CI brief — competitive landscape report
• TERAZOSIN HYDROCHLORIDE updates RSS · CI watch RSS